Other Events ·
On July 20, 2026, Anavex Life Sciences Corp. submitted a Compliance Plan to Nasdaq to regain compliance with Listing…
AVXLAnavex Life Sciences Corp.
On July 20, 2026, Anavex Life Sciences Corp. submitted a Compliance Plan to Nasdaq to regain compliance with Listing Rule 5250(c)(1) following a deficiency notice received on May 20, 2026. The deficiency resulted from the company's failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. While the common stock continues to trade under the symbol "AVXL", the company's listing status depends on the Nasdaq Staff's review of the plan. Anavex Life Sciences Corp. is a biotechnology company that develops therapeutic candidates for neurological disorders.